Pharma stocks in focus: Why Cipla, Zydus and Biocon matter on Friday
Cipla flagged temporary supply constraints for Lanreotide, Zydus won final USFDA approval for a blood-disorder drug, while Biocon strengthened its balance sheet via a Rs 4,150-crore QIP.
Cipla flagged temporary supply constraints for Lanreotide, Zydus won final USFDA approval for a blood-disorder drug, while Biocon strengthened its balance sheet via a Rs 4,150-crore QIP.
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
